Hepatitis B Immune Globulin I.V. Approval Could Rely On Open-Label Studies, Historical Controls – FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency's briefing materials for the March 18 meeting of the Blood Products Advisory Committee note that prospective trials could be difficult because HBIGIV is currently used off-label in combination with antiviral drugs.
You may also be interested in...
Nabi-HB Decision Anticipated “Shortly” Following FDA Advisory Committee Review
FDA’s Blood Products Advisory Committee recommended approval of Nabi’s BLA for the treatment of liver transplant patients.
Nabi-HB Decision Anticipated “Shortly” Following FDA Advisory Committee Review
FDA’s Blood Products Advisory Committee recommended approval of Nabi’s BLA for the treatment of liver transplant patients.
Biopure’s Hemopure BPAC Review To Be Closed-Door
The day before Biopure's July 14 review, FDA's Blood Products Advisory Committee will discuss Nabi's Nabi-HB immunoglobulin for hepatitis B.